# Kimia Therapeutics

> Kimia Therapeutics is a Berkeley-based biotech building ATLAS, a drug-discovery platform that pairs nanoliter-scale high-throughput precision chemistry with machine learning and genome editing to map the druggable space at single-atom resolution. Spun out of Carmot Therapeutics in 2023 and backed by $55M in Series A funding, Kimia is using its chemical atlas to advance therapeutic programs in cancer and immunology.

- **Founded:** 2023
- **Headquarters:** Berkeley, California, United States
- **Founders:** Stig K. Hansen (Co-founder & CEO), Jack Sadowsky (Co-founder & VP, Discovery Chemistry), Ray Fucini (Co-founder & Senior Director, Discovery Platform Technology)
- **Team size:** ~37 employees
- **Products:** ATLAS Platform, Direct-to-Biology (D2B) Workflows, Discovery Pipeline
- **Notable:** Raised $55M Series A in December 2023, co-led by The Column Group and Dimension., Spun out of Carmot Therapeutics (later acquired by Roche in 2024) with rights to Chemotype Evolution outside metabolic disease., Recruited Imran S. Haque, PhD, as Chief Technology Officer in March 2025.

## Products & services

- **ATLAS Platform** — AcTive Learning with Automated Synthesis - a high-throughput, nanoliter-scale chemistry platform that generates billions of drug-like compounds and feeds chemical synthesis and assay data back into ML models for continuous compound design.
- **Direct-to-Biology (D2B) Workflows** — Integrates automated synthesis with genome editing and biological assays to take compounds from design to functional readout without traditional purification bottlenecks.
- **Discovery Pipeline** — Internal therapeutic programs in oncology and immunology, plus undisclosed targets pursued through pharma partnerships.

## Achievements

- Raised $55M Series A in December 2023, co-led by The Column Group and Dimension.
- Spun out of Carmot Therapeutics (later acquired by Roche in 2024) with rights to Chemotype Evolution outside metabolic disease.
- Recruited Imran S. Haque, PhD, as Chief Technology Officer in March 2025.
- Built nanoliter-scale chemistry stack capable of accessing billions of drug-like compounds.

## Latest updates

- **2025-03** — Appointed Imran S. Haque, PhD, as Chief Technology Officer to lead machine learning and computational chemistry.
- **2023-12** — Emerged from stealth with $55M Series A co-led by The Column Group and Dimension, joined by Horizons Ventures.
- **2023-01** — Launched as a spin-out of Carmot Therapeutics.

## Links

- Website: https://kimiatx.com
- LinkedIn: https://www.linkedin.com/company/kimia-therapeutics

---

Profile page: https://yespress.io/kimia-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-29